Last reviewed 2025-12-24 · How we verify
Home › Trials › NCT04081714 Intermediate Expanded Access Protocol CNMAu8.EAP03
NCT04081714
TEMPORARILY_NOT_AVAILABLE
This is a single-center intermediate expanded access program to provide access to the investigational product, CNM-Au8, up to 25 participants diagnosed with Multiple Sclerosis.
Details
Lead sponsor Clene Nanomedicine Status TEMPORARILY_NOT_AVAILABLE
Conditions
Interventions
Countries United States
Source: ClinicalTrials.gov. Drug Landscape entry: https://druglandscape.com/trial/NCT04081714.
See also: ClinicalTrials.gov record .
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.